Concepedia

Author

Michael Dukes

AstraZeneca (United Kingdom)

Also Known As

M Dukes, M. Dukes, M.N.G. Dukes, Michael Dukes

23

Publications

3.7K

Citations

12

H-Index

37

Concepts

All Affiliations

AstraZeneca (United Kingdom)East Cheshire NHS Trust
MD

About

Michael Dukes is an author at AstraZeneca (United Kingdom) specializing in medicine, pharmacology, and pharmacotherapy.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

10

10

2.9K

2

Natural Sciences

2

2

1.1K

3

Biochemistry

2

2

397

4

Health Sciences

1

1

54

5

Cell Biology

1

1

802

Michael Dukes

×

12

Publications

3.7K

Citations

11

H-Index

YearCitations

A potent specific pure antiestrogen with clinical potential.

A. E. Wakeling, Michael Dukes, Jean Bowler

PubMed

1991

1.1K

ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration.

Stephen R. Wedge, Donald Ogilvie, Michael Dukes,

PubMed

2002

802

AZD2171: A Highly Potent, Orally Bioavailable, Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase Inhibitor for the Treatment of Cancer

Stephen R. Wedge, Jane Kendrew, Laurent Hennequin,

Cancer Research

2005

706

Novel 4-Anilinoquinazolines with C-7 Basic Side Chains:  Design and Structure Activity Relationship of a Series of Potent, Orally Active, VEGF Receptor Tyrosine Kinase Inhibitors

Laurent Hennequin, Elaine S. E. Stokes, Andrew P. Thomas,

Journal of Medicinal Chemistry

2002

308

Arimidex�: A potent and selective fourth-generation aromatase inhibitor

Paul V. Plourde, Martin C. Dyroff, Michael Dukes

Breast Cancer Research and Treatment

1994

257

ZD4190: an orally active inhibitor of vascular endothelial growth factor signaling with broad-spectrum antitumor efficacy.

Stephen R. Wedge, DJ Ogilvie, Michael Dukes,

PubMed

2000

194

The preclinical pharmacology of “Arimidex” (Anastrozole; ZD1033) — a potent, selective aromatase inhibitor

Michael Dukes, Philip N. Edwards, M. S. Large,

The Journal of Steroid Biochemistry and Molecular Biology

1996

89

Effects of a non-steroidal pure antioestrogen, ZM 189,154, on oestrogen target organs of the rat including bones

Michael Dukes, R Chester, L Yarwood,

Journal of Endocrinology

1994

66

Antiuterotrophic effects of a pure antioestrogen, ICI 182,780: magnetic resonance imaging of the uterus in ovariectomized monkeys

Michael Dukes, Diane Miller, A. E. Wakeling,

Journal of Endocrinology

1992

61

Dynamic contrast-enhanced MRI of vascular changes induced by the VEGF-signalling inhibitor ZD4190 in human tumour xenografts

D. Checkley, Jean Tessier, Stephen R. Wedge,

Magnetic Resonance Imaging

2003

54

Page 1